Stay updated with breaking news from Caredx Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In CareDx, Inc. v. Natera, Inc., Court of Appeals for the Federal Circuit held CareDx’s patent claims to methods of detecting organ transplant rejection were invalid as patent ineligible under 35 U.S.C. section 101. Claims to medical diagnostics face unique challenges.
JACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical Practice - read this article along with other careers information, tips and advice on BioSpace
After reflecting upon the events of the past twelve months, Patent Docs presents its 16th annual list of top patent stories. For 2022, we identified ten stories that were covered on...
/PRNewswire/ -- The "The World Market for Molecular Diagnostics Tests, 11th Edition" report has been added to ResearchAndMarkets.com's offering. In this...
/PRNewswire/ -- The "Global Molecular Diagnostics Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering. The...